adeno-associated virus-mediated LDLR/PCSK9 intervention for familial hypercholesterolemia.
作者信息
Han Zeyu, Tan Cheng, Ai Jianzhong, Zhu Ye
机构信息
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Department of Cardiology, Institute of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
出版信息
Genes Dis. 2025 Apr 10;12(6):101632. doi: 10.1016/j.gendis.2025.101632. eCollection 2025 Nov.
Abstract
摘要
相似文献
1
adeno-associated virus-mediated LDLR/PCSK9 intervention for familial hypercholesterolemia.
Genes Dis. 2025 Apr 10;12(6):101632. doi: 10.1016/j.gendis.2025.101632. eCollection 2025 Nov.
2
AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.
Circ Res. 2014 Aug 29;115(6):591-9. doi: 10.1161/CIRCRESAHA.115.304008. Epub 2014 Jul 14.
4
Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
J Am Coll Cardiol. 2014 Jun 10;63(22):2365-73. doi: 10.1016/j.jacc.2014.02.538. Epub 2014 Mar 12.
5
Methylation status of , and is associated with cardiovascular events in familial hypercholesterolemia.
Epigenomics. 2024;16(11-12):809-820. doi: 10.1080/17501911.2024.2351792. Epub 2024 Jun 17.
6
The impact of gene variants on the thickness and softness of the Achilles tendon in familial hypercholesterolemia.
Atherosclerosis. 2022 Oct;358:41-46. doi: 10.1016/j.atherosclerosis.2022.08.014. Epub 2022 Aug 30.
7
Structural dynamics of LDL receptor interactions with E498A and R499G variants of PCSK9.
J Mol Model. 2025 May 19;31(6):161. doi: 10.1007/s00894-025-06380-1.
8
Patients With and Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia.
J Am Heart Assoc. 2021 Feb 16;10(4):e018263. doi: 10.1161/JAHA.120.018263. Epub 2021 Feb 3.
9
A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis.
Acta Pharmacol Sin. 2024 Oct;45(10):2119-2133. doi: 10.1038/s41401-024-01305-9. Epub 2024 May 29.
10
Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia.
Arterioscler Thromb Vasc Biol. 2022 Jul;42(7):e203-e216. doi: 10.1161/ATVBAHA.122.315499. Epub 2022 May 5.
本文引用的文献
1
Genetic and molecular architecture of familial hypercholesterolemia.
J Intern Med. 2023 Feb;293(2):144-165. doi: 10.1111/joim.13577. Epub 2022 Oct 17.
2
Familial Hypercholesterolemia: JACC Focus Seminar 4/4.
J Am Coll Cardiol. 2021 Nov 2;78(18):1831-1843. doi: 10.1016/j.jacc.2021.09.004.
3
Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors.
J Nutr. 2017 Apr;147(4):473-481. doi: 10.3945/jn.116.235069. Epub 2017 Feb 8.
4
Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
Endocr Metab Immune Disord Drug Targets. 2008 Dec;8(4):238-43. doi: 10.2174/187153008786848286.
5
NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.
J Biol Chem. 2004 Nov 19;279(47):48865-75. doi: 10.1074/jbc.M409699200. Epub 2004 Sep 9.
Zotero 插件